- Head of Biotech Private Investments
United States, Institutional
Change
The views expressed are those of the author at the time of writing. Other teams may hold different views and make different investment decisions. The value of your investment may become worth more or less than at the time of original investment. While any third-party data used is considered reliable, its accuracy is not guaranteed. For professional, institutional, or accredited investors only.
Nilesh Kumar, Head of Biotech Private Investments, explores innovation in obesity, autoimmunity, and oncology, emphasizing drugs that solve real-world unmet medical needs.
Expert
Read next
Showing
of
Insights Posts
Article
5 min
Looking beyond mega-caps
We explore how the growing concentration of capital in mega-cap private companies is reshaping the venture and growth opportunity set, and the implications for portfolio construction, manager selection, diversification, and potential return opportunities across private markets.
5 min
Article
2027-06-30
Article
5 min
IPO readiness through a public and private market lens
Our Value Creation Team brings together portfolio company leaders and Wellington investors to explore key issues shaping private markets, with takeaways from a recent IPO market discussion.
5 min
Article
2027-07-02
Article
8 min
Private biotech investing deep dive
We explore the distinct characteristics of private biotech investing, including how the asset class differs from traditional venture capital and how clinical milestones, specialized underwriting, and portfolio construction shape its risk, return, and diversification potential.
8 min
Article
2028-05-31
Article
4 min
The IPO market inflection
Our late-stage private market experts explore how a small cohort of scaled, AI-driven IPOs could reshape distributions, public-market structure, and exit decisions across the venture ecosystem.
4 min
Article
2027-05-31
Video
3 min
Physical AI, robotics, and Encord
Greg Wasserman, Head of Private Climate Investing, explores the rise of physical AI across robotics, drones, and autonomous systems, and the growing role of machine vision and data infrastructure in enabling real-world deployment.
3 min
Video
2027-04-30
Article
5 min
The role of secondaries in venture and growth private equity
Our experts discuss how secondaries are reshaping venture capital and growth markets, offering liquidity and strategic portfolio diversification opportunities.
5 min
Article
2027-04-30
Video
6 min
2026 Venture Capital Roundtable
Our three-part video series brings together experts from across our venture capital platform to explore opportunities outside of AI, how to identify quality among today’s noise, and what investors may be underestimating for the year ahead.
6 min
Video
2027-02-28
Article
5 min
Private equity deep dive
We explore four key private equity questions to help investors better understand how these strategies compare and complement each other in a portfolio. In particular, we highlight the distinct opportunity sets, risk-return characteristics, and portfolio roles of venture capital and buyout strategies.
5 min
Article
2027-02-28
Article
7 min
Secondary investment: Flexibility in private equity
Our private equity experts highlight how secondary transactions offer liquidity solutions for LPs, capital support for GPs, and a growing opportunity set.
7 min
Article
2027-03-31
Article
4 min
China’s biotech surge (and its impact on biotech venture capital)
China’s biotech sector’s long-term potential is underpinned by lower costs, faster development timelines, and increasingly translatable clinical data. In our new paper, we explore the implications for US and European biotechs.
4 min
Article
2028-01-31
Article
6 min
Why materiality assessments (still) matter
Our Value Creation Team explores why materiality assessments matter for private companies and outlines a practical five-step approach to identifying the issues that most influence financial performance, resilience, and long-term value.
6 min
Article
2027-12-31
URL References
Related Insights